INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

Pomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a misleading manner despite previous warnings. The disclosure triggered a 21.12% stock price decline. Investors have until May 26, 2026, to request Lead Plaintiff status.

05/26/2026, 4:00 PM • GlobeNewswire

IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 may be entitled to compensation.

05/25/2026, 7:22 PM • GlobeNewswire

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

05/25/2026, 9:48 AM • GlobeNewswire

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

05/22/2026, 6:11 PM • GlobeNewswire

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The announcement caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization. Hagens Berman is investigating claims that ImmunityBio intentionally misled investors.

05/22/2026, 12:48 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging that company defendants made materially false and misleading statements regarding Anktiva's capabilities and the company's business prospects. The lawsuit covers investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026. The lead plaintiff deadline is May 26, 2026.

05/20/2026, 12:00 PM • GlobeNewswire

ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug

ImmunityBio's stock rose 8.12% in premarket trading after the FDA accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The FDA assigned a PDUFA target action date of January 6, 2027. The Phase 2/3 QUILT 3.032 trial demonstrated strong efficacy with a 12-month disease-free survival rate of 58.2% and 96.0% disease-specific survival at 36 months.

05/20/2026, 8:49 AM • Benzinga

ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies

ImmunityBio presented comparative analyses showing its ANKTIVA plus BCG combination achieved higher complete response rates (69.7%) against nadofaragene firadenovec-vncg (53.4%) and longer response duration (22.1 vs 9.7 months). Against TAR-200, ANKTIVA showed comparable efficacy with significantly fewer adverse events (61.7% vs 83.5%), representing a 68% reduction in treatment-related side effects for BCG-unresponsive bladder cancer patients.

05/19/2026, 12:57 PM • Benzinga

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that defendants made false and misleading statements regarding Anktiva's capabilities and the company's business operations during the Class Period (January 19, 2026 - March 24, 2026). Investors who purchased ImmunityBio securities during this period and suffered losses have until May 26, 2026, to apply to be appointed as lead plaintiff.

05/18/2026, 5:40 PM • GlobeNewswire

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ImmunityBio announced an exclusive U.S. development and supply agreement with Japan BCG Laboratory for Tokyo-172 BCG to treat bladder cancer, backed by positive Phase 3 trial data showing non-inferiority to TICE BCG. The company also secured five U.S. patents for its ANKTIVA plus BCG platform through 2035. Despite the news, IBRX shares fell 1.13% to $7.88 on Monday.

05/18/2026, 10:20 AM • Benzinga

IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for ImmunityBio, Inc. (NASDAQ: IBRX) regarding a securities class action lawsuit. The complaint alleges that defendants issued materially false and misleading statements about Anktiva's capabilities during the class period of January 19, 2026 to March 24, 2026. Shareholders who purchased shares during this period are encouraged to register by the May 26, 2026 deadline.

05/15/2026, 9:00 AM • GlobeNewswire

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.

05/14/2026, 2:45 PM • GlobeNewswire

Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon

Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.

05/14/2026, 6:22 AM • Investing

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS

Rosen Law Firm is reminding investors in Gossamer Bio, ImmunityBio, and Immutep Ltd. about upcoming deadlines to join securities class action lawsuits. The lawsuits allege that defendants made false and misleading statements to investors, with Gossamer Bio specifically accused of concealing material adverse facts concerning its Phase 3 PROSERA study design. Investors who purchased securities during specified class periods may be eligible for compensation.

05/13/2026, 2:47 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) alleging securities fraud. The complaint claims that company defendants made materially false and misleading statements regarding Anktiva's capabilities and misrepresented the company's business, operations, and prospects. Investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 are eligible to join the case, with a lead plaintiff deadline of May 26, 2026.

05/13/2026, 12:00 PM • GlobeNewswire